СОВРЕМЕННЫЕ ПЕРОРАЛЬНЫЕ МИОРЕЛАКСАНТЫ В КОМПЛЕКСНОЙ ТЕРАПИИ БОЛЕВЫХ СИНДРОМОВ
Номер журнала:
3
Год издания:
2017
Рассмотрены вопросы лечения центральной спастичности и миофасциальных синдромов с применением пероральных миорелаксантов и другой терапии. Дан ряд рекомендаций по организации ведения пациентов такого профиля. Представлены данные литературы о лечении спастичности пероральными миорелаксантами.
Ключевые слова:
неврология
спастичность
миофасциальный синдром
лечение
баклофен
Для цитирования
Васильев А. СОВРЕМЕННЫЕ ПЕРОРАЛЬНЫЕ МИОРЕЛАКСАНТЫ В КОМПЛЕКСНОЙ ТЕРАПИИ БОЛЕВЫХ СИНДРОМОВ
. Врач, 2017; (3): 25-30 Список литературы:
- Pandyan A., Gregoric M., Barnes M. et al. Spasticity: clinical perceptions, 367 neurological realities and meaningful measurement // Disabil. Rehabil. – 2005; 27: 2–6.
- Bhadra N. Neuroprostheses for spasticity control. In: Kilgore K, editor. Implantable neuroprostheses for restoring function / Cambridge: Elsevier, 2015; 331.
- Ertzgaard P., Anhammer M., Forsmark A. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap // Acta Neurol. Scand. – 2017; 135 (3): 366–72.
- Brainin M., Norrving B., Sunnerhagen K. et al. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications // Int. J. Stroke. – 2011; 6: 42–6.
- Ryu J., Lee J., Lee S. et al. Factors predictive of spasticity and their effects on motor recovery and functional outcomes in stroke patients // Top Stroke Rehabil. – 2010; 17: 380–8.
- Jensen R., Olesen J. et al. Tension-type headache: an update on mechanisms and treatment // Cur. Opin. Neurol. – 2000; 13 (3): 285–9.
- Исайкин А.И., Кузнецов И.В., Кавелина А.В. и др. Фасеточный синдром: причины возникновения, клиника, диагностика и лечение // Consilium Medicum. (Прил.). – 2016; 2: 53–61.
- Deyo R., Weinstein J. Low Back Pain // N. Engl. J. Med. – 2001; 344 (5): 363–70.
- Henschke N., Maher C., Refshauge K. et al. Prevalence of and screening for serious spinal pathology in patient presenting to primary care settings with acute low back pain // Arthritis Rheum. – 2009; 60 (10): 3072–80. Doi: 10.1002/art.24853
- Manchikanti L., Standiford Helm, Vijay Singh et al. Algorithmic Approach for Clinical Management of Chronic Spinal Pain // Pain Physician. – 2009; 12: 225–64.
- De Palma M., Ketchum J., Saullo T. What is the source of chronic low back pain and does age play a role? // Pain Med. – 2011; 12 (2): 224–33.
- Васильев А.С., Васильева В.В. Междисциплинарные аспекты ведения пациентов с синдромом торакалгии // Кремлевская медицина. Клинический вестник. – 2013; 3: 62–5.
- Парфенов В.А., Батышева Т.Т. Боли в спине: болезненный мышечный спазм и его лечение миорелаксантами // Лечащий врач. – 2013; 4: 16–8.
- Drug Monograph. Baclofen https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-56
- Katz P., Gerson L., Vela M. Guidelines for the diagnosis and management of gastroesophageal reflux disease // Am. J. Gastroenterol. – 2013; 108: 308–28.
- Fromm G., Terrence C., Chattha A. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up // Ann. Neurol. – 1984; 15: 240–4.
- Васильева В.В., Шмырев В.И., Васильев А.С. Мышечнотонический дисбаланс у детей первых недель и месяцев жизни // Врач. – 2010; 1: 8–10.
- Duncan G., Shahani B., Young R. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study // Neurology. – 1976; 26: 441–6.
- Feldman R., Kelly-Hayes M., Conomy J. et al. Baclofen for spasticity in multiple sclerosis.Double-blind crossover and three-year study // Neurology. – 1978; 28: 1094–8.
- Sawa G., Paty D. The use of baclofen in treatment of spasticity in multiple sclerosis // Can. J. Neurol. Sci. – 1979; 6: 351–4.
- Milla P., Jackson A. A controlled trial of baclofen in children with cerebral palsy // J. Int. Med. Res. – 1977; 5: 398–404.
- Medaer R., Hellebuyk H., Van den Brande E. et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo // Acta Ther. – 1991; 17: 323–31.
- Smolenski Ch., Muff S., Smolenski-Kautz S. A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis // Curr. Med. Res. Opin. – 1981; 7: 374–83.
- Stien R., Nordal H., Oftedal S. et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine* compared with baclofen // Acta Neurol. Scand. – 1987; 75: 190–4.
- Medici M., Pebet M., Ciblis D. A double-blind, long-term study of tizanidine (‘Sirdalud’)in spasticity due to cerebrovascular lesions // Curr. Med. Res. Opin. – 1989; 11: 398–405.
- Hoogstraten M., van der Ploeg R., vd Burg W. et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients // Acta Neurol. Scand. – 1988; 77: 224–30.
- Bresolin N., Zucca C., Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial // Adv. Ther. – 2009; 26: 563–73.
- Baclofen Tablet package insert. Sellersville, PA: Teva Pharmaceuticals USA, 2010 Jun.
- Lioresal (baclofen) injection package insert. Minneapolis, MN: Medtronic, Inc., 2016 Sep.